Results 91 to 100 of about 535,273 (259)

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Primal Generation, Dual Judgment: Self-Training from Test-Time Scaling

Code generation is typically trained in the primal space of programs: a model produces a candidate solution and receives sparse execution feedback, often a single pass/fail bit. Test-time scaling enriches the inference procedure by sampling multiple candidates and judging among them, but the comparative information this process reveals is discarded ...
Jiao, Yizhu, Zhang, Ruixiang, Bai, Richard, Han, Jiawei, Collobert, Ronan, Zhang, Yizhe   +5 more
openaire   +2 more sources

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

Dual-Dimensional Consistency: Balancing Budget and Quality in Adaptive Inference-Time Scaling

Large Language Models (LLMs) have demonstrated remarkable abilities in reasoning. However, maximizing their potential through inference-time scaling faces challenges in trade-off between sampling budget and reasoning quality. Current strategies remain inefficient as they typically treat sampling width and depth as orthogonal objectives, where width ...
Xu, Rongman, Li, Yifei, Zhao, Tianzhe, Wu, Yanrui, Li, Bo, Yan, Hang   +5 more
openaire   +2 more sources

Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant, Tise Suzuki, Kiera McGivney, V. S. S. Abhinav Ayyadevara, Sharon Asariah, Jay Deng, Ethan Nyein, Jacqueline Coats, Gary Yu, Yevgeniya J. Ioffe, Christian Hurtz, Juli J. Unternaehrer   +11 more
wiley   +1 more source

Dynamic graph convolutional traffic flow prediction model based on attention and linear layer fusion

大数据
Accurate traffic volume prediction is crucial for optimizing the operational efficiency of road networks and alleviating urban traffic congestion. Traditional models rely on predefined static graph structures, making it difficult to capture dynamic ...
Wei Hui, Xiao Hongbo, Zou Beiji, Kui Xiaoyan, Xiao Jianhua, He Jiaju, He Niguli   +6 more
doaj  

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Quantifying Spatiotemporal Heterogeneity of Tumor Metabolism and Vasculature with a Multiparametric Point-of-Investigation Microscope

BME Frontiers
Objective: The aim of this study was to develop and apply a dual-scale Capillary-Cell (CapCell) microscope to quantify spatial and temporal heterogeneity in tumor metabolism and vasculature during anti-angiogenic therapy.
Enakshi D. Sunassee, Marcia Cunha Dos Santos, Riley J. Deutsch-Williams, Sanjana Sankholkar, Megan Madonna, Gregory Palmer, Nirmala Ramanujam   +6 more
doaj   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

ADP‐ribosylation: An emerging regulator of the epigenome

Molecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho, Chenqian Liu, W. Lee Kraus   +2 more
wiley   +1 more source